Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subhashis Banerjee

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 29, 2012
Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbαYouseung Shin, Romain Noel, Subhashis Banerjee, et al.
The Journal of Dermatology|December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 studyYayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Shalabh Singhal, Raymond Darbenzio, et al.
Dermatology and Therapy|September 2, 2021
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 InhibitorsAnjaneya Chimalakonda, James Burke, Lihong Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2012
Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonistsRomain Noel, Xinyi Song, Youseung Shin, et al.
Annals of the Rheumatic Diseases|March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Journal of Neurosurgery|April 4, 2015
Quantitative analysis of the Kawase versus the modified Dolenc-Kawase approach for middle cranial fossa lesions with variable anteroposterior extensionManjul Tripathi, Rama Chandra Deo, Ashish Suri, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsMark C Genovese, Maria Greenwald, Chul-Soo Cho, et al.
Environmental Toxicology and Pharmacology|January 6, 2009
Role of oxidative stress in the promoting activities of pcbsHoward P Glauert, Job C Tharappel, Zijing Lu, et al.
Toxicology and Applied Pharmacology|July 23, 2008
Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kappa B in miceHoward P Glauert, Job C Tharappel, Subhashis Banerjee, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Bioorganic & Medicinal Chemistry Letters|May 29, 2012
Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbαYouseung Shin, Romain Noel, Subhashis Banerjee, et al.
The Journal of Dermatology|December 6, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 studyYayoi Tada, April W Armstrong, Shinichi Imafuku, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy SubjectsAnjaneya Chimalakonda, Shalabh Singhal, Raymond Darbenzio, et al.
Dermatology and Therapy|September 2, 2021
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 InhibitorsAnjaneya Chimalakonda, James Burke, Lihong Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|May 8, 2012
Synthesis and SAR of tetrahydroisoquinolines as Rev-erbα agonistsRomain Noel, Xinyi Song, Youseung Shin, et al.
Annals of the Rheumatic Diseases|March 4, 2022
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J Mease, Atul A Deodhar, Désirée van der Heijde, et al.
Journal of Neurosurgery|April 4, 2015
Quantitative analysis of the Kawase versus the modified Dolenc-Kawase approach for middle cranial fossa lesions with variable anteroposterior extensionManjul Tripathi, Rama Chandra Deo, Ashish Suri, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsMark C Genovese, Maria Greenwald, Chul-Soo Cho, et al.
Environmental Toxicology and Pharmacology|January 6, 2009
Role of oxidative stress in the promoting activities of pcbsHoward P Glauert, Job C Tharappel, Zijing Lu, et al.
Toxicology and Applied Pharmacology|July 23, 2008
Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kappa B in miceHoward P Glauert, Job C Tharappel, Subhashis Banerjee, et al.
Pageof 12